Trump announces reforms to accelerate access to psychedelic drug treatments
Summary
President Donald Trump signed an executive order to speed up the review of psychedelic drugs like ibogaine for medical use, especially to help treat conditions such as post-traumatic stress disorder (PTSD). The order includes $50 million in federal funding for research on these drugs, which are mostly illegal now but may be reclassified if clinical trials show success.Key Facts
- President Trump signed an executive order to speed up FDA reviews of psychedelic drugs.
- The focus drug, ibogaine, is believed to help treat PTSD and substance abuse.
- The U.S. will dedicate $50 million to research on ibogaine and similar drugs.
- Ibogaine is made from a root of a shrub found in central Africa.
- Texas has already committed $50 million to studying ibogaine.
- Psychedelic drugs like ibogaine can cause hallucinations and are mostly illegal now.
- Health Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan were present at the announcement.
- Kennedy has criticized the FDA for suppressing psychedelics, and Rogan supports their responsible use and legalization.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
